益气和胃胶囊联合瑞巴派特治疗慢性非萎缩性胃炎的临床研究

目的探讨益气和胃胶囊联合瑞巴派特片治疗慢性非萎缩性胃炎的临床疗效。方法选取2018年2月—2018年10月在荆州市中心医院进行治疗的94例慢性非萎缩性胃炎患者为研究对象,根据用药方案的不同分为对照组和治疗组,每组各47例。对照组口服瑞巴派特片,0.1g/次,3次/d;治疗组在对照组基础上口服益气和胃胶囊,2.0g/次,3次/d。两组均治疗4周。观察两组的临床疗效,比较两组的症状积分、血清学指标水平、胃黏膜炎症积分、胃黏膜炎症病理积分。结果治疗后,对照组和治疗组的总有效率分别为80.85%、95.74%,两组比较差异有统计学意义(P0.05)。治疗后,两组胃脘痞胀、胃脘疼痛、食欲不振、嗳气积分均明显降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组症状积分明显低于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组胃泌素(GAS)、胃动素(MTL)、前列腺素E2(PGE2)水平均显著升高,表皮生长因子(EGF)水平显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗后,治疗组血清学指标明显优于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组胃黏膜炎症积分、胃黏膜炎症病理积分均明显降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗后,治疗组胃黏膜炎症积分、胃黏膜炎症病理积分明显低于对照组,两组比较差异有统计学意义(P0.05)。结论益气和胃胶囊联合瑞巴派特片特治疗慢性非萎缩性胃炎具有较好的临床疗效,可改善患者临床症状、胃黏膜炎症及病理情况,促进机体血清GAS、MTL、EGF、PGE2水平增高,具有一定的临床推广应用价值。

Clinical study on Yiqi Hewei Capsules combined with rebamipide in treatment of chronic non-atrophic gastritis

Objective To explore the clinical efficacy of Yiqi Hewei Capsules combined with Rebamipide Tablets in treatment of chronic non-atrophic gastritis. Methods Patients (94 cases) with chronic non-atrophic gastritis in Jingzhou Central Hospital from February 2018 to August 2018 were randomly divided into control and treatment groups, and each group had 47 cases. Patients in the control group were po administered with Rebamipide Tablets, 0.1 g/time, three times daily. Patients in the treatment group were po administered with Yiqi Hewei Capsules on the basis of the control group, 2.0 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and symptom scores, serological indicators levels, scores of gastric mucosal inflammation, and pathological scores of gastric mucosal inflammation in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.85% and 95.74%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of epigastric distension, epigastric pain, loss of appetite, belching in two groups were significantly decreased (P<0.05). And the scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of GAS, MTL, PGE2 in two groups were significantly increased, but the levels of EGF in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, scores of gastric mucosal inflammation and pathological scores of gastric mucosal inflammation in two groups were significantly decreased (P<0.05). And the serological indicators levels in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Yiqi Hewei Capsules combined with Rebamipide Tablets has clinical curative effect in treatment of chronic non-atrophic gastritis, can improve the clinical symptoms, gastric mucosal inflammation and pathological conditions, and promote the increase of serum GAS, MTL, EGF and PGE2 levels, which has a certain clinical application value.